Iglesias JF, Heg D, Roffi M, et al. - Researchers compared percutaneous coronary intervention with biodegradable polymer sirolimus-eluting stents (BP-SES) vs durable polymer everolimus-eluting stents (DP-EES) in patients with diabetes mellitus (DM), focusing on long-term clinical outcomes, in a prespecified subgroup analysis of the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization) trial. Stratification by diabetic status was done in patients randomly allocated to ultrathin-strut BP-SES or thin-strut DP-EES. Target lesion failure, a composite of cardiac mortality, target vessel myocardial infarction, and clinically indicated target lesion revascularization, at 5 years was considered as the primary endpoint. Findings revealed that clinical outcomes did not differ throughout 5 years between patients with DM managed with ultrathin-strut BP-SES or thin-strut DP-EES.